25.10.2023 07:45:00

Vistin Pharma ASA: New CEO appointed

Oslo, Norway, 25th of October 2023

The Board of Directors of Vistin Pharma ASA has appointed Magnus Tolleshaug as the new CEO of Vistin Pharma from 1st of January 2024. Magnus Tolleshaug is currently the CCO in Vistin Pharma, and will replace the current CEO, Kjell-Erik Nordby. Kjell-Erik has been the CEO of Vistin Pharma since the company was established in 2015 and has decided to retire. Magnus started his career in Vistin 1st of March 2020 and has been instrumental in delivering Vistin’s ambitious growth strategy. Before Magnus joined Vistin, he worked for many years in Takeda Pharmaceuticals as «Head of Global Launch Excellence & Product Lifecycle Management». Magnus has more than 20 years of experience from the global pharmaceutical industry and various international leadership roles.

During Kjell-Erik’s leadership Vistin’s Metformin business has seen more than 300% revenue growth and he has been essential in transforming Vistin into a well-recognized world leading Metformin producer.

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.



 

 

 

 


Nachrichten zu Vistin Pharma ASAmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Vistin Pharma ASAmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Vistin Pharma ASA 1,97 0,25% Vistin Pharma ASA